CovalX and Bruker Daltonics Announce Strategic Collaboration
News Jun 06, 2013
Currently manufacturing the third generation of high mass detection systems, the HM3, CovalX´s technology is already well recognized as a unique tool for protein-protein interactions analysis, which includes stoichiometry, biotherapeutic aggregation, epitope mapping and immunocomplex characterization; all key applications for the biotech and pharmaceutical industries.
Bruker Daltonics is a leading supplier of life-science systems offering the growing proteomics research community a wide choice of MS-based research tools. Increasing the information content and understanding of protein complexes through the addition of stoichiometric data, inhibition, and aggregation, this molecular interaction data promises to offer new insights for protein researchers worldwide.
“With this strategic collaboration Bruker strengthens its market-leading position in the field of MALDI-TOF Mass Spectrometry by bridging the gap to new application fields in the analysis of protein complexes. The interaction of both CovalX and Bruker technologies will allow the customers to perform protein-protein interaction studies on an advanced level” said Ralf Schäfer – Global Product Manager MALDI TOF MS of Bruker Daltonics Life Science and Clinical Division (LSC).
Pioneering Method Enables Screening Millions of Human Antibodies for Rapid Therapeutic DiscoveryNews
A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery.READ MORE
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.